Roivant Sciences Ltd.
ROIV
$27.85
-$0.25-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -593.91% | -107.77% | -109.73% | -103.70% | -102.43% |
| Total Depreciation and Amortization | -44.80% | -40.20% | -28.55% | -36.48% | 135.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 104.38% | 93.57% | 94.08% | 88.46% | 88.90% |
| Change in Net Operating Assets | 114.40% | -128.96% | -43.98% | -924.82% | -307.17% |
| Cash from Operations | 2.10% | 1.12% | -20.17% | -9.69% | 7.24% |
| Capital Expenditure | -87.55% | -444.88% | -359.50% | -315.45% | -445.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -71.62% | -95.71% | -93.51% | -93.51% | -94.96% |
| Other Investing Activities | 104.89% | 110.25% | -39,490.21% | -24,566.67% | -609,044.88% |
| Cash from Investing | 107.71% | -71.06% | -154.80% | -133.94% | -153.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -158.52% | -196.83% | -128.02% | -290.55% |
| Issuance of Common Stock | 459.90% | 535.16% | 429.55% | 50.83% | 38.12% |
| Repurchase of Common Stock | 47.82% | 3.51% | -28.03% | -3,431.85% | -11,562.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -52.76% | -52.76% | -52.76% | -100.00% |
| Cash from Financing | 102.40% | -1.70% | -200.31% | -390.87% | -262.35% |
| Foreign Exchange rate Adjustments | 414.96% | -89.64% | 877.94% | -63.91% | -86.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.05% | -229.06% | -204.74% | -178.73% | -191.05% |